RaySearch Laboratories (RAY) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
23 Dec, 2025Executive summary
Net sales reached SEK 323 million in Q4 2024, up 8% year-over-year, and SEK 1.192 billion for the full year, up 17% year-over-year, marking a record high.
Operating profit was SEK 74 million in Q4 (23% margin) and SEK 260 million for the year (22% margin), both significantly improved from prior year and exceeding the 2026 margin target.
Support revenue grew 14% in 2024, now 40% of total sales, driven by new license sales and high customer retention.
Board proposed increasing the dividend to SEK 3 per share, reflecting strong financial position and outlook.
Strong cash position of SEK 463 million at year-end, with stable cash flow and no loans.
Financial highlights
Q4 order intake was SEK 305 million, down 4% year-over-year; full-year order intake grew 8% to SEK 1.087 billion.
License sales in Q4 were SEK 160 million, up 16% year-over-year; support revenue was SEK 131 million, up 9%.
Full-year license revenue was SEK 575.5 million (+30%), support revenue SEK 472.9 million (+14%), and hardware revenue SEK 109.2 million (down from SEK 128.4 million).
Q4 profit after tax was SEK 60 million; full-year profit after tax was SEK 203.5 million.
Cash flow from operations in Q4 was SEK 103 million; full-year cash flow from operations improved to SEK 485 million.
Outlook and guidance
Positive outlook for order intake and revenue growth in 2025, with continued momentum expected.
Operating margin target raised to at least 25% by 2026, up from previous 20%, after exceeding the target in 2024.
No drastic changes in OPEX planned for 2025; growth in headcount and investments to continue at a similar pace as previous years.
Latest events from RaySearch Laboratories
- Record sales, strong margins, and major clinical milestones drive confidence for 2026.RAY
Q4 202512 Feb 2026 - Record sales, strong margins, and robust backlog signal continued growth and innovation.RAY
Q2 20241 Feb 2026 - Record Q3 sales, margin growth, and RayCare milestones prompt a higher 2026 target.RAY
Q3 202415 Jan 2026 - Q2 sales and profit declined, but strong H1 order intake and support revenue support a positive outlook.RAY
Q2 202523 Nov 2025 - Record Q1 sales, strong order intake, and margin expansion signal robust growth momentum.RAY
Q1 202520 Nov 2025 - Record Q3 sales and profit, with strong order intake and accelerating Pinnacle conversions.RAY
Q3 20257 Nov 2025